Biodistribution and dosimetry of the GluN2B-specific NMDA receptor PET radioligand (R)-[ 11 C]Me-NB1.

Lucas RischkaMatej MurgašVerena PichlerChrysoula VrakaIvo RauschDietmar WinklerLukas NicsSazan RasulLeo Robert SilberbauerMurray Bruce ReedGodber Mathis GodbersenJakob UnterholznerPatricia HandschuhGregor GryglewskiThomas MindtMarkus MitterhauserAndreas HahnSimon Mensah AmetameyWolfgang WadsakRupert LanzenbergerMarcus Hacker

Published in: EJNMMI research (2022)

C]Me-NB1 was well-tolerated without reported side effects. Effective dose was estimated to 1.8 mSv when using 300 MBq of presented radioligand. The critical organ was the urinary bladder. Due to the low effective dose coefficient of this radioligand, longitudinal studies for drug development and treatment monitoring of neuropsychiatric disorders including neurodegenerative diseases are possible. Trial registration Registered on 11th of June 2019 at https://www.basg.gv.at (EudraCT: 2018-002933-39).

Keyphrases

pet imaging
study protocol
pet ct
positron emission tomography
cross sectional
randomized controlled trial
combination therapy
diffusion weighted imaging